Compound name
GSK973
Protein family
Bromodomain
Target name
BRDT@BD2
Affinity biochemical (nM)
39.8
CG-Set
Epigenetic set
Recommended Concentration
1 µM
Compound EUbOPEN ID
EUB0001113a
SMILES
[H][C@@]12COC[C@@]2([H])[C@@H]1NC(c1cc(C(NC)=O)c2c(c1)[C@H](c1ccccc1)[C@@H](CF)O2)=O
InChIKey
WZQLVEPIBAOOGF-RMMWZPCPSA-N
NCBI gene ID
676
UniProt ID
Q58F21
Synonyms
BRD6, CT9
Mode of action
Inhibitor
Negative control
GSK943
Affinity biochemical definition
IC50
Affinity biochemical assay type
BET mutant TR-FRET assay (BD2)
Affinity Biochemical Source Knowledge
https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247
Affinity biochemical relation
0
Selectivity platform
BROMOScan (DiscoverX)
Selectivity platform number of targets
40
Selectivity remarks
In-vitro potencies of closest targets in BROMOScan (DiscoverX): pKd(TAF1, BD2) = 6.4, pKd(TAF1L, BD2) = 5.7, pKd(BRD9) = 5.7, pKd(CECR2) = 5.5, pKd(BAZ2A) = 5.5, pKd(BAZ2B) = 5.1; Selective for the BD2 domain of BET proteins; Clean in selectivity screen against 48 targets (GPCRs, ion-channels, other targets); Chemoproteomics data (3 vectors) showed excellent non BCPs selectivity; Screened at 10 µM against 45 GPCRs (PDSP screen), in-vitro potencies of closest targets: Ki(DRD3) = 257.47 nM, Ki(DRD4) = 982.65 nM, Ki(DRD2) = 964.05 nM
Selectivity Source Knowledge
https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00247
Selectivity Number of Off-targets
0